Becton, Dickinson (BDX) insider buying and selling
Every Table I transaction reported by directors and officers of S&P 500 companies on SEC Form 4 filings (2 business days to file): each row labeled with its official transaction code, nothing filtered out beforehand.
Open-market purchases (code P) are the rare signal, in green; sales (code S) are common and often pre-scheduled (10b5-1). Table II (derivatives) is not included: its prices are exercise prices, not market values. Guide: insider buying.
| Date | Ticker | Insider | Role | Shares | Price | Amount | % of stake | Type / filing |
|---|
Download these transactions as CSV No account, no sign-up. The data is public: it comes from SEC Form 4 filings.
Becton, Dickinson and Company (BDX) insider buying and selling: no purchases, 24 sales
76 Form 4 Table I transactions filed with the SEC by Becton, Dickinson and Company insiders between 2025-08-26 and 2026-09-29 (15-month history): 0 open-market purchases and 24 sales, plus 52 transactions under other Form 4 codes, broken down one by one below. The largest open-market trade is a sale of $768k by Polen Thomas E Jr on 2026-08-13.
Becton, Dickinson insider buying and selling over the last 12 months
Between Oct 21, 2025 and Oct 20, 2026, Becton, Dickinson insiders filed 21 sales worth $2.8M on the open market, and no purchases.
The biggest seller was Polen Thomas E Jr (Chairman, CEO and President): $1.2M in 2 sales, out of 5 different sellers.
The largest trade of the period was a sale of $768k on Aug 13, 2026, by Polen Thomas E Jr (Chairman, CEO and President), under a 10b5-1 plan. Form 4 on sec.gov (0001628280-26-057166).
Of the 21 sales, 18 (86%, $2.1M) carry the 10b5-1 plan flag on the Form 4, meaning they were scheduled months ahead; the other 3 do not.
The last three months show 5 sales, against 6 in the three before. The latest sale from Sep 28, 2026.
Against its sector (Healthcare, 59 companies with an insider page on this site), over the same dates the median is 9 sales and 0 purchases on the open market. Becton, Dickinson has more sales than 47 of the other 58, ranks 41 of 59 by net dollars sold, and 19 of the 59 have at least one purchase.
The 20 most important trades
With no open-market purchases, the table starts with BDX's sales, largest first. The full history is in the tool above, already searched.
See all 76 BDX trades in the full history →
| Trade date | Filed | Insider | Role | Amount | Code | Filing |
|---|---|---|---|---|---|---|
| 2026-08-13 | 2026-08-14 | Polen Thomas E Jr | Chairman, CEO and President | $768k | S — Open-market sale (scheduled 10b5-1) | SEC |
| 2026-08-11 | 2026-08-12 | Goette Roland | EVP and President, EMEA | $441k | S — Open-market sale2 Form 4 footnotesF1 Securities sold were common stock acquired through the Becton, Dickinson and Company Global Share Investment Program (the "GSIP"). F2 Holdings reflect the addition of dividends the reporting person received as part of the equity adjustment made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. | SEC |
| 2026-06-01 | 2026-06-03 | Polen Thomas E Jr | Chairman, CEO and President | $405k | S — Open-market sale (scheduled 10b5-1)2 Form 4 footnotesF1 The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $145.21 through $147.49. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. F2 Direct holdings reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. to the number of shares underlying previously reported and unvested time-vested restricted stock units held by the reporting person. | SEC |
| 2026-01-15 | 2026-01-16 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | $334k | S — Open-market sale (scheduled 10b5-1) | SEC |
| 2026-02-18 | 2026-02-18 | Scott Bertram L | Director | $174k | S — Open-market sale | SEC |
| 2025-09-10 | 2025-09-11 | Fraser Claire | Director | $172k | S — Open-market sale | SEC |
| 2026-06-10 | 2026-06-11 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | $167k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 Direct holdings reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. to the number of shares underlying previously reported and unvested time-vested restricted stock units held by the reporting person. | SEC |
| 2026-06-24 | 2026-06-25 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | $160k | S — Open-market sale (scheduled 10b5-1) | SEC |
| 2025-12-17 | 2025-12-17 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | $123k | S — Open-market sale (scheduled 10b5-1) | SEC |
| 2025-11-07 | 2025-11-07 | Scott Bertram L | Director | $38k | S — Open-market sale | SEC |
| 2026-08-26 | 2026-08-27 | Feld Michael | EVP, Chief Revenue Officer | $31k | S — Open-market sale (scheduled 10b5-1) | SEC |
| 2026-01-26 | 2026-01-28 | Feld Michael | EVP, CRO & Pres. Life Sciences | $15k | S — Open-market sale (scheduled 10b5-1) | SEC |
| 2025-12-26 | 2025-12-29 | Feld Michael | EVP, CRO & Pres. Life Sciences | $15k | S — Open-market sale (scheduled 10b5-1) | SEC |
| 2025-12-01 | 2025-12-02 | Feld Michael | EVP, CRO & Pres. Life Sciences | $15k | S — Open-market sale (scheduled 10b5-1) | SEC |
| 2026-09-28 | 2026-09-29 | Feld Michael | EVP, Chief Revenue Officer | $14k | S — Open-market sale (scheduled 10b5-1) | SEC |
| 2026-02-26 | 2026-02-27 | Feld Michael | EVP, Chief Revenue Officer | $14k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 Direct holdings reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. to the number of shares underlying previously reported and unvested time-vested restricted stock units held by the reporting person. | SEC |
| 2026-07-27 | 2026-07-28 | Feld Michael | EVP, Chief Revenue Officer | $12k | S — Open-market sale (scheduled 10b5-1) | SEC |
| 2026-03-26 | 2026-03-27 | Feld Michael | EVP, Chief Revenue Officer | $12k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 This reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 7, 2025. | SEC |
| 2026-06-26 | 2026-06-26 | Feld Michael | EVP, Chief Revenue Officer | $11k | S — Open-market sale (scheduled 10b5-1) | SEC |
| 2025-08-22 | 2025-08-26 | Feld Michael | EVP & President, Life Sciences | $11k | S — Open-market sale (scheduled 10b5-1) | SEC |
The period balance: money in, money out
In the Form 4 filings submitted between Aug 26, 2025 and Sep 29, 2026 there is not one open-market purchase of Becton, Dickinson and Company: 24 sales worth $3.0M and zero dollars bought.
Only codes P and S count, where an insider puts in or takes out their own money. A selling balance like Becton, Dickinson and Company's is the norm in the S&P 500, where much of the pay comes as stock. It is not a recommendation to buy or sell: it is what was filed.
Every transaction, code by code
| Code | What it means | Trades | Reported amount |
|---|---|---|---|
| A | Grant or award | 30 | $0 |
| S | Open-market sale | 24 | $3.0M |
| F | Tax withholding (shares surrendered for taxes) | 16 | $0 |
| D | Sale back to the issuer | 3 | $10.3M |
| M | Option exercise | 3 | $10.3M |
| Total | Everything filed in the period | 76 | $23.6M |
46 of the 76 rows carry no usable amount on the Form 4: they count as trades and add $0. The code labels come from the SEC index.
Who has traded
Over the 15 months of history, 26 distinct people or entities have filed Becton, Dickinson and Company transactions: none bought on the open market and 6 sold. Counted by CIK, the fixed number the SEC gives each filer, and not by name, which each filer types their own way.
Of the 6 who sold on the open market (24 sales in all), the three biggest sellers account for $2.4M of the $3.0M: 81% of the money in three people.
| Filer | Role | Transactions | Bought (count) | Sold (count) | Last filed |
|---|---|---|---|---|---|
| Polen Thomas E Jr | Chairman, CEO and President | 8 | — | $1.2M (2) | 2026-08-14 |
| Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | 8 | — | $784k (4) | 2026-06-25 |
| Goette Roland | EVP and President, EMEA | 3 | — | $441k (1) | 2026-08-12 |
| Scott Bertram L | Director | 3 | — | $212k (2) | 2026-02-18 |
| Feld Michael | EVP, Chief Revenue Officer | 17 | — | $193k (14) | 2026-09-29 |
| Fraser Claire | Director | 1 | — | $172k (1) | 2025-09-11 |
| Byrd Richard | EVP & President Interventional | 3 | — | — | 2025-12-01 |
| Delorefice Christopher | EVP & Chief Financial Officer | 3 | — | — | 2025-12-01 |
Shown here are the 8 who moved the most money, out of 26. The rest are in the full history, one link above. The name links to all their trades, in any company. "Transactions" counts any code; the money, open market only. Role: from their latest filing.
Month by month
By the month the trade was executed, not the month it was filed; months with no trades show zero. The busiest month was Jun 2026: 0 purchases and 4 sales, worth $743k. 1 of the 15 months have none.
| Month | Purchases | Amount | Sales | Amount |
|---|---|---|---|---|
| Aug 2025 | 0 | $0 | 1 | $11k |
| Sep 2025 | 0 | $0 | 2 | $182k |
| Oct 2025 | 0 | $0 | 1 | $11k |
| Nov 2025 | 0 | $0 | 1 | $38k |
| Dec 2025 | 0 | $0 | 3 | $152k |
| Jan 2026 | 0 | $0 | 2 | $349k |
| Feb 2026 | 0 | $0 | 2 | $188k |
| Mar 2026 | 0 | $0 | 1 | $12k |
| Apr 2026 | 0 | $0 | 1 | $11k |
| May 2026 | 0 | $0 | 1 | $11k |
| Jun 2026 | 0 | $0 | 4 | $743k |
| Jul 2026 | 0 | $0 | 1 | $12k |
| Aug 2026 | 0 | $0 | 3 | $1.2M |
| Sep 2026 | 0 | $0 | 1 | $14k |
| Oct 2026 | 0 | $0 | 0 | $0 |
The last month may be partial: a Form 4 is filed up to two business days later. The table does not say whether the pattern is good or bad; it says when it happened.
Becton, Dickinson and Company (BDX) analysis page →
Other Healthcare companies with insider trades
All 500 are listed in the section index →
Which insiders are buying their own company stock →
How to read this data
16 of the 20 sales in the table are flagged as scheduled (10b5-1 plan): signed months ahead and executed automatically, so they say nothing about what the insider thinks today. Becton, Dickinson has no open-market purchase (code P) in the history, the most common case in the S&P 500: insiders are already paid in stock. The latest filing is from Sep 29, 2026, and a Form 4 arrives up to two business days after the trade.
5 of the 20 rows in the table carry footnotes from the Form 4 itself, folded into the code column and copied verbatim; a row with no footnote means the filing has none.
Guide: Insider buying · all guides
What is behind these trades
The concepts on this page, explained from scratch in the Academy. Free, no account.
- What the efficiency hypothesis says and what it does NOT sayIf an insider's purchase is public and anyone can read it, is there any information left in it? That is the exact question that brings people here.
- Who really moves the market: the types of investorWho sits on the other side of each order, and where a company's own insiders fit among them.
- Supply, demand and price: why it rises and falls constantlyHow a piece of news ends up inside the price, and why the reaction to a filed sale is rarely the one you would expect.
Source: SEC EDGAR Form 4. This is a list of public facts, not financial advice or a recommendation to buy or sell.